Kuerten has an average return of 4.8% when recommending Qiagen.
According to TipRanks.com, Kuerten is ranked #6846 out of 7591 analysts.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $53.02, a 5.4% upside from current levels. In a report issued on July 14, Kepler Capital also downgraded the stock to Hold with a EUR42.00 price target.
The company has a one-year high of $59.00 and a one-year low of $45.33. Currently, Qiagen has an average volume of 774.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.